News | August 08, 2021
Cipla posts net profit at Rs 715 crores
India business contributes to a stellar performance
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The company has already embarked upon significant expansion in Turkey
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
